A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration ...

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and ...

New research confirms the romiplostim biosimilar GP40141 offers comparable efficacy and safety for treating immune ...

Canadian study reveals no significant differences in remission outcomes between etanercept biosimilars and the originator, ...

Number 5: New research shows that denosumab biosimilar SB16 is equivalent to the reference product, Prolia (denosumab), up to ...

A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim ...

Number 5: The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions. Number 4: In a news roundup piece, audiences can ...